-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Tops Q3 EPS by 9c
-
-
-
-
-
-
-
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
-
-
-
-
-
-
-
TD Cowen Reiterates Sell Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Announces FDA Approval of CASGEVY
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Tops Q2 EPS by 115c
-
-
-
-
-
-
-
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
-
-
-
-
-
-
-
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
-
1,199,390 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

